Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530672 | 0.85 | OPRD1 (0.43) | OPRD1KCNH2HRH3ALPIPKM | |
| SCHEMBL4525259 | 0.77 | CHRM2 (0.39) | CHRM2CHRM3KCNH2HRH3TACR2 | |
| SCHEMBL18174280 | 0.69 | MITF (0.36) | CHRM2CHRM3OPRD1OPRM1 | |
| SCHEMBL10184132 | 0.69 | ALPI (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4081808 | 0.68 | CTSD (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8294303 | 0.67 | F2 (0.52) | OPRD1ALPIPKMPTGS1XIAP | |
| SCHEMBL13898950 | 0.67 | ALPI (0.51) | OPRD1ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28743119 | 0.66 | SLC7A5 (0.73) | CHRM2KCNH2ALPIPKMPTGS1 | |
| Phenylalanine SCHEMBL28743116 | 0.66 | SLC7A5 (0.73) | CHRM2KCNH2ALPIPKMPTGS1 | |
| SCHEMBL5992407 | 0.66 | ALDH1A1 (0.73) | CHRM2CHRM3OPRD1KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | CHRM2 2389/4885CHRM3 2380/4885OPRD1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.